$RLMD SEC Filings

Filed On	Filing
11 Sep 2026	Form 4: Shenouda Maged, Chief Financial Officer Bought 120,200 shares ($505K) · Bought 79,800 shares ($339K)
11 Sep 2026	Form 4: Traversa Sergio, Director Bought 100,000 shares ($418K) · Bought 100,000 shares ($410K)
08 Sep 2026	8-K: Other Events Dr. Raj S. Pruthi’s employment as Chief Medical Officer – Urology of Relmada Therapeutics, Inc., ended on September 3, 2026.
14 Aug 2026	SCHEDULE 13G/A
06 Aug 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
06 Aug 2026	QUARTERLY REPORT
29 Jul 2026	SCHEDULE 13G
28 Jul 2026	8-K: Regulation FD Disclosure
22 Jun 2026	SCHEDULE 13G
18 Jun 2026	REGISTRATION STATEMENT
09 Jun 2026	SCHEDULE 13G
28 May 2026	8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
13 May 2026	SCHEDULE 13G/A
13 May 2026	REGISTRATION STATEMENT
12 May 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
12 May 2026	QUARTERLY REPORT
04 May 2026	SCHEDULE 13G
17 Apr 2026	DEFINITIVE ADDITIONAL MATERIALS
17 Apr 2026	Proxy statement: annual meeting on May 27, 2026 CEO pay $8.9M, up 394%
09 Apr 2026	EFFECT

Comments